Fate Therapeutics (FATE) Payables (2012 - 2026)

Fate Therapeutics' Payables history runs 15 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• Quarterly Payables fell 21.79% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 21.79% YoY) and the FY2025 annual result came in at $2.7 million, down 71.64% from the prior year.
• Payables was $3.3 million for Q1 2026 at Fate Therapeutics, up from $2.7 million in the prior quarter.
• Across five years, Payables topped out at $11.4 million in Q1 2022 and bottomed at $2.7 million in Q4 2025.
• A 5-year average of $6.5 million and a median of $6.3 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables surged 98.45% — and 2025, when it tumbled 71.64%.
• Fate Therapeutics' Payables stood at $8.3 million in 2022, then plunged by 42.9% to $4.7 million in 2023, then surged by 98.45% to $9.4 million in 2024, then tumbled by 71.64% to $2.7 million in 2025, then grew by 23.38% to $3.3 million in 2026.
• Business Quant data shows FATE's Payables at $3.3 million in Q1 2026, $2.7 million in Q4 2025, and $3.5 million in Q3 2025.